Form 4: Inhibitor Therapeutics Director Samuel P. Sears Jr. Acquires 50,000 Shares of Common Stock
SEC Form 4 Filing
Director Samuel P. Sears Jr. acquired 50,000 shares of Inhibitor Therapeutics common stock as compensation.
Summary
- On April 1, 2025, Samuel P. Sears Jr., a director of Inhibitor Therapeutics, Inc., acquired 50,000 shares of common stock.
- The acquisition was made as compensation under the Issuer's 2014 Equity Incentive Plan.
- The price per share was $0.
- Following the transaction, Sears directly owns 1,279,543 shares of Inhibitor Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction, and while insider buying can be seen as positive, it's compensation-related, so it doesn't strongly indicate personal investment confidence.
Positives
- The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future.
Industry Context
This filing is a routine disclosure related to insider transactions and doesn't necessarily reflect broader industry trends.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of Earliest Transaction |
| 04/01/2025 | Transaction Date: Acquisition of 50,000 shares of common stock |
| 04/07/2025 | Date of Signature |
Keywords
Inhibitor Therapeutics, INTI, Samuel P. Sears Jr., Director, Common Stock, Equity Incentive Plan, Beneficial Ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.